Please find attached intimation regarding incorporation of a wholly owned subsidiary company in Netherlands

August 13, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Intimation of incorporation of a wholly owned subsidiary company in Netherlands Ref.: Regulation 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) In continuation of our earlier intimation dated July 11, 2026, and pursuant to Regulations 30 and 51 of the Listing Regulations, we wish to inform you that, as disclosed therein, the proposed wholly owned subsidiary has been incorporated in the Netherlands today, i.e., August 13, 2026, under the name and style of “Mankind Pharma (Netherlands) B.V.” The detailed disclosures as required under the Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“SEBI Circular”), were already provided by the Company in its intimation dated July 11, 2026. You are requested to kindly take the above information on record. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer